Publication of a transparency notification received from François Fornieri

Liège, BelgiumMithras (Euronext Brussels: MITRA), a company dedicated to Women’s health announcement, in accordance with article 14 of Belgian law

May 2, 2007 concerning the publication of significant holdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that he has received a transparency notification from Mr. Francois Fornieri, to January 07, 2022.

Mr. Fornieri notified Mithra that it fell below the legal threshold of 25% on December 17

2021, following the temporary borrowing of shares linked to the exercise by the Company of a put option on 20 December 2021 under the capital commitment agreement with Capital LDA Limited 1. Mr. Fornieri will redeem its loaned shares upon full realization of the put option. Mr. Fornieri now owns 24.94% (10,984,330 shares) of the 44,051,259 shares currently in circulation. Previously, Mr. Fornieri tenuous

25.44% of the 44,051,259 shares outstanding.

Detailed transparency notifications are available on the Mithra Investors website ( An updated overview of Mithra’s shareholder structure will be included in Mithra’s corporate governance charter, which will be available on its website.


Benoit Mathieu


T: +32 473 35 80 18

E: [email protected]

Maud Vanderthommen


T: +32 473 58 61 04

E: [email protected]

About Mithra

Mithras (Euronext: MITRA) is a Belgian biotechnology company dedicated to the transformation Women’s health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products that offer greater efficiency, safety and convenience, meeting the needs of women throughout their lives. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications for women’s health and beyond. After successfully launching the first estetrol-based product in 2021, the contraceptive pill Is she, Mithra is now focusing on its second product Donesta, the next generation hormone therapy. Mithra also develops and manufactures complex therapies in the fields of contraception, menopause and hormone-dependent cancers. It offers its partners a full spectrum of research, development and specialized manufacturing on its Mithra CDMO technological platform. Active in more than 100 countries around the world, Mithra employs approximately 300 people and is headquartered in Liège, Belgium.


Important information

The content of this announcement includes statements which are, or may be considered, “forward-looking statements”. These forward-looking statements may be identified by the use of forward-looking terminology, including the words “believes”, “believes”, “anticipates”, “expects”, “intends”, “may”. , ‘Will’, ‘plan’ ‘,’ continue ‘,’ in progress’, ‘potential’, ‘predict’, ‘project’, ‘target’, ‘seek’ or ‘should’, and include company statements regarding the expected results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that such forward-looking statements are not guarantees of future performance. The actual results of the Company may differ materially from those predicted by forward-looking statements. The Company assumes no obligation to publicly update or revise forward-looking statements, except as required by law.

Jacob L. Thornton